Best KRAS, NRAS,BRAF mutation testing doctors: TOP 31 doctors

Dr. Mustafa Solak is a medical oncologist with expertise in breast, testicular, ovarian, lung, head-neck, and gastrointestinal cancers. He graduated from Hacettepe University School of Medicine. He completed his residency at Istanbul Sisli Etfal Teaching and Research Hospital. He then pursued a fellowship at Hacettepe University Cancer Institute.

Dr. Solak has managed many complex cancer cases. He has contributed to clinical advancements at respected centers, including the University of Texas MD Anderson Cancer Center. He has also worked at Hitit University Corum Training Hospital and Medical Park Hospital. His experience shows a strong commitment to cancer care and research.

Dr. Sertkaya graduated from Konya Meram Science High School in 2001 and entered Gazi University Medical Faculty the same year, graduating in 2008. He completed his urology specialization at Haydarpaşa Numune Training and Research Hospital in 2014, becoming a urology specialist.

Since becoming a specialist, he has focused on the sub-branch of Andrology, attending various training sessions and conferences and performing surgeries with some of the world's leading Andrology professors. In 2017, he passed the written and oral proficiency exams conducted by the European Association of Urology, earning the title of "FEBU."

In 2020, Dr. Sertkaya achieved the rank of Associate Professor of Urology. His journey in Urology and Andrology, which began in 2008, continues at the Andro Expertise Male Health and Aesthetics Center, which he founded in 2022. He sees patients in his own clinic and performs surgeries at affiliated hospitals.

Education and Career

2011 – 2015, (Internal Medicine Specialist) Istanbul University Istanbul School of Education and Career

Medicine Department of Internal Medicine

2015 – 2016, (Internal Medicine) Specialist Istanbul Haydarpasa Numune Training and Research Hospital

2016 – 2019, (Medical Oncology) Istanbul University Istanbul School of Medicine Department of Medical Oncology

2019 – 2021, (Medical Oncology Specialist) - Istanbul Haydarpasa Numune Training and Research Hospital

2021 – 2024, (Associate Professor) Marmara University School of Medicine Department of Medical Oncology

Memberships in Scientific Organizations

ASCO

ESMO

TTOD 

AVOD 

Publications

In the field of oncology, he has published over 30 peer-reviewed articles at both international and national levels.

Awards Received

EAACI The European Academy of Allergy and Clinical Immunology 2019 Best Poster Award

"The top 3rd verbal presentation, IGICC (11th International Gastrointestinal Cancers Conference – IGICC2021)"

Speeches Delivered at National Congresses, Conferences, and Symposia:

Courses, Meetings, and Certificates

ESMO certified Medical Oncologist since 2019

Education and Specialization

• Faculty of Medicine, Hacettepe University
• 1999 - Akdeniz University, Faculty of Internal Medicine, Internal Medicine Specialization Training
• Internal Medicine Specialization Training in the USA, Akdeniz University (2013 - 2014)
• Internal Medicine Specialization Training in the USA (2013 - 2014) - Medical Oncology Department
• Akdeniz University, Faculty of Medicine, Department of Medical Oncology (Received Associate Professorship title)

Work Experience

• 2009 - Kayseri Training and Research Hospital, Hospital
• Acıbadem Kayseri
• 2017 - 2018 - Lara Private Anadolu Hospital
• 2018 - Medical Park Antalya Hospital Complex

Expertise

• Diagnosis of organ tumors
• Chemotherapy in cancer treatment
• Targeted cancer therapies
• Immunotherapy in cancer treatment
• Next-generation genetic research in cancer treatment
• Complementary medicine in cancer treatment
• Medical oncology

Experience

2021 year - 2022 year

Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

2021 year - 2022 year

Department of Radiation Oncology, Biruni University Faculty of Medicine

2020 year - 2021 year

Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

2017 year - 2020 year

Clinical Manager of Radiation Oncology, Neolife Medical Center

2016 year - 2017 year

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2011 year - 2016 year

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2010 year - 2011 year

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2008 year - 2010 year

Radiation Oncology Clinic, Samsun Training and Research Hospital (Education Coordinator)

2006 year

Medical Faculty, Dokuz Eylül University

2006 year - 2008 year

Radiation Oncology Clinic, Samsun Mehmet Aydın State Hospital (Compulsory Service)

2000 year - 2006 year

Medical Faculty, Dokuz Eylül University

Education

2022 year

Biruni University Faculty of Medicine, Department of Radiation Oncology, Faculty Member, Professor Doctor

2022 year

Anadolu University Open Education Faculty Undergraduate Program, Cultural Heritage and Tourism

2021 year

Feyziye Schools Foundation Işık University Health Services Vocational School, Faculty Member, Associate Professor Doctor

2017 year

Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Faculty Member

2017 year

Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Associate Professor Doctor

2006 year

Samsun Training and Research Hospital, Specialist Doctor, Compulsory Service

2006 year

Dokuz Eylül University Faculty of Medicine, Department of Radiation Oncology, Medical Specialization

1998 year

Ege University, Faculty of Medicine

Dr. Auala Hubert is a board-certified medical oncologist and radiotherapist with 33 years of clinical experience. She works at Hadassah Medical Center and speaks both English and Hebrew. Dr. Hubert leads the Gastrointestinal Cancer Center. She is also a senior physician in the Oncology Department.

She earned her M.D. from Hadassah University Hospital. She holds board certifications in oncology and radiotherapy. Dr. Hubert has passed USMLE Parts I and II. She is a member of the Israel Society of Clinical Oncology, Israel Medical Society, and Israel Cancer Association. Dr. Hubert also serves on several medical and social service committees, where she helps advance cancer care.

Dr. Sullivan graduated in Medicine and Surgery from the National University of Rosario in 2005, specializing in Medical Oncology through the MIR at the Santa Creu i Sant Pau Hospital (HSCiSP, 2012) in Barcelona.

She received a post-MIR scholarship from the Ministry of Interior from HSPiSP (2012) and then a pre-doctoral scholarship from ISCiii (Rio Hortega – 2013-2015).

In 2014, he moved to Paris where he obtained a DUERTECC diploma at the Gustave Roussy University Hospital (Villejuif), followed by an ESMO scholarship (Georges Mathé Translator Scholarship), which he received in 2016.

Since January 2017, he has been working on the staff of the Medical Oncology Department of the HSCiSP. In the same year, he obtained his PhD from the Autonomous University of Barcelona.

Since 2015, he has been a member of the Board of Directors of the Spanish Lung Cancer Group (GECP). And since 2022, he has been the coordinator of the HSCiSP Committee on Neuroendocrine Tumors.

In November 2021, she joined the IOR Medical Oncology Service and is actively involved in various research projects in the Pangea Lab under the supervision of Dr. Molina.

Dr. Sullivan is involved in several clinical trials in lung cancer and neuroendocrine tumors, many of which have been presented at various international scientific meetings.

She has participated in national and international conferences and is an author and co-author of research articles published in influential journals.

She is currently a member of the Spanish Society of Medical Oncology (SEOM), GECP, European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Organization for Research and Treatment of Cancer (EORTC) and the Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE).

One of the best cancer specialists in Europe, educator, and cancer researcher, President of the Central European Cooperative Oncology Group (CECOG).
Has published over 600 scientific papers on cancer treatment.

Known Expertise 

Medical Oncologist 

Academic Position 

Senior Lecturer 

Education

Bar-Ilan University, Israel / Computational Biology 

Israeli Society for Health-Tech / Fellowship by IMA/ Innovation and Entrepreneurship in Medicine and Health-Tech 

Sheba Medical Center and Bar-Ilan University, Israel/ Genomics and Biomedical Informatics 

Semmelweis University/Doctor of Medicine 

Training and Specialization 

Clinical observership in acute oncology, early phase clinical trials and lung cancer/ Guy's and St. Thomas hospital, London, England 

Leader Shift, Executive Development Program, Tel-Aviv Sourasky Medical Center 

Fellowship Program in Innovation and Entrepreneurship in Medicine and Health-Tech 

Resident, Medical Oncology, TASMC, Israel 

6th year medical school rotations, Kaplan Medical Center, Israel 

Rotation, intensive care unit and pulmonology, Stony Brook hospital, NY, US 

Clinical Experience 

Leader of the TASMC oncology project of PSIFAS, the Israeli National Genomic Medicine Initiative 

PI for study initiator trial: T-Cell Repertoire sequencing as clinical efficacy tool for pembrolizumab (with platinum based chemotherapy) in advanced NSCLC. 

PI for study initiator trial: T-cell repertoire sequencing as a clinically efficacy tool for neoadjuvant immunotherapy plus platinum-doublet chemotherapy for resectable NSCLC. 

Representative of the National Medical Association for the National Council for the Prevention, Diagnosis and Treatment of Malignant Diseases, as well as head of the oncology field, Leumit HMO 

Consultant on drugs and operations in the field of oncology, Leumit HMO 

Member of the Helsinki Committee for Clinical Studies, TASMC 

Primary investigator (PI) in pharmaceutical phases I&III clinical trials Head of oncology day-care service, TASMC, Israel 

Molecular Tumor Board (MTB) moderator of the Israeli Lung Cancer Society 

NGS interpretation clinic alongside head of pathology, TASMC, Israel 

PI for study initiator trial: Genomic Variant of BCL-2 as a Novel Predictor of Response to Paclitaxel, TASMC, Israel 

Medical oncology clinic in the field of lung and breast cancer, TASMC, Israel

Leading sub-investigator (SI) in many phase I-III clinical trials in oncology, including intra-tumoral injections (mRNA, viruses and NO), TASMC, Israel 

Courses 

Good Clinical Practice ICH GCP R2 & Israeli MOH Guidelines Updated Course 

Point-of-Care Ultrasound course, Israeli Medical Association 

GCP training Bioforum 

GCP training Bioforum

Investigator Site Personnel ICH GCP Training Certificate - TransCelerate BioPharma 

Academic Experience 

Lecturer in the Department of Medical Education at the Faculty of Medical and Health Sciences at Tel Aviv University 

JIMS Journal Club - Instructor for students. 

Guidance of Dr. Aviv Berkovich M.D in basic science: cfDNA NGS for identification ofprimary and acquired resistance in patients with Lung Cancer and EGFR mutations. 

TASMC, Israel in collaboration with The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, NY USA 

Training team for oncology residents, TASMC, Israel 

Mentor for new intern, TASMC, Israel 

Tutor for medical students in oncology clerkships, Tel-Aviv University, Israel 

Honors 

Outstanding teacher in the faculty of medicine, Tel-Aviv University, Israel

 Outstanding teacher in the faculty of medicine, Tel-Aviv University, Israel 

Sign of honor for reserve medical personnel for the battle in Lebanon, IDF

Completion of residency final examination (shlav Beit) with honors 

Israeli society for clinical oncology and radiation therapy (ISCORT) 17 research grant competition winner 

Affiliations 

Israeli Medical Association (IMA) 

Israeli Society for Clinical Oncology and Radiation Therapy (ISCORT) 

The Israeli Lung Cancer Group (ILCG) 

European Society of Medical Oncology (ESMO) 

International Association for the Study of Lung Cancer (IASLC) 

The International Society of Liquid Biopsy (ISLB) 

The Israeli Society for Health-Tech 

Boards 

Co-founder, board member and treasurer of the Israeli Acute Oncology Society 

Clinical Research Association Board of Directors on behalf of the Israeli Lung Cancer Group 

Member of the Trustees of Oncology Innovation, TASMC, Israel 

Doctor of Medical Service IDF 

Areas of interest 

Thoracic malignancies, 

early to late phase clinical trials, 

intra-tumoral injections, 

comprehensive genomic profiling of tumors, 

liquid biopsies: cfDNA, TCR rep-seq and epi-Genetics; 

cell therapy

Dr. Viola Fox is the Chief Physician at the Clinic for Haematology, Oncology, and Palliative Medicine at BKZ Solingen. This clinic is a certified interdisciplinary cancer center. Dr. Fox is a leading expert in drug therapy for tumor diseases in Germany and Europe. She has more than 15 years of experience in this field.

She is a member of the German Society of Oncology and Haemato-oncology (GDHO), the German Association of Physicians, and the American Association for Cancer Research. Dr. Fox is also active in molecular biology research. Her work supports progress in cancer treatment and molecular diagnostics.

Her main areas of expertise are chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Dr. Fox is known for her innovative methods and strong commitment to patient care. Her efforts have led to high recovery rates and recognition from her peers.

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

• 2004-2011: İnönü University Faculty of Medicine
• 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
• 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

• 2016-2017: Bingöl City Hospital, Internal Medicine
• 2021-2022: Health Sciences University, Medical Oncology
• 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
• 2023-2024: Ohio State University, Medical Oncology
• 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

• 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
• 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

• 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
• 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
• 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
• 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
• 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

• Ongoing: ECFMG Certification
• 2024: CITI Responsible Conduct of Research (The Ohio State University)
• 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
• 2024: CITI Human Subjects Protection (The Ohio State University)
• 2024: CITI Good Clinical Practice (The Ohio State University)
• 2023: Occupational English Test (OET)
• 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
• 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
• 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

• American Society of Clinical Oncology (ASCO) - 2022
• Turkish Society of Medical Oncology - 2020

Dr. Elnur Sahibov is a licensed Radiation Oncologist with 8 years of medical training and clinical experience. He completed his undergraduate and specialization studies at Marmara University Faculty of Medicine. From 2012 to 2016, he focused on advanced radiation oncology techniques.

Dr. Sahibov is known for his expertise in cancer treatment. He has helped improve patient outcomes and uses evidence-based protocols. He is accredited by leading medical institutions and is dedicated to ongoing professional development in oncology.

Dr. Ilker Nihat Okten is a board-certified medical oncologist. He is accredited by the European Society of Medical Oncology (ESMO). Dr. Okten has worked as a sub-investigator in several phase III clinical trials. His work has helped advance cancer treatment. He specializes in chemotherapy, immunotherapy, targeted therapy, hormonal therapy, and palliative care.

He is a member of ESMO, ASCO, and the Turkish Society of Medical Oncology. Dr. Okten has published several articles in oncology. He is active in both research and clinical practice.

Dr. Raj Nagarkar is a leading Surgical Oncologist with 19 years of experience. He has performed over 50,000 cancer surgeries. His main focus areas are Breast and Thoracic Surgical Oncology. He is involved in more than 200 clinical trials and has contributed to many national and international publications.

Dr. Nagarkar trained in Surgical Oncology at Tata Memorial Hospital, Mumbai. He also holds an MRCS from the Royal College of Surgeons, Edinburgh. He teaches DNB Superspecialty Surgical Oncology and Breast Surgery at Maharashtra University of Health Sciences. Dr. Nagarkar is dedicated to improving the quality of life for his patients.

Prof. Dr. med. Ulrich Graven

Head of the Clinic of Hematology, Oncology and Gastroenterology

Head of a certified oncology center

Head of Clinical Research Department

Specialization:

Hematology, including stem cell transplantation

Abdominal oncology, especially colorectal and pancreatic cancer therapy

Metastasis therapy, including the use of off-label drugs

Membership in professional societies:

Professional Union of German Therapists

German Society for Internal Medicine

German Cancer Society

Abdominal Oncology Working Group

German Society of Hematology and Oncology

German Working Group on Bone Marrow and Hematopoietic Stem Cell Transplantation

German Society for Digestive and Metabolic Diseases

European Society for Medical Oncology

American Society of Clinical Oncology

American Association for Cancer Research

Activities in professional communities:

German Cancer Society:

Since 2013, speaker of the commission for certification of oncology centers

Since November 2007, member of the board

Since September 2022, Speaker of the Section of National Societies on Cancer Control

Chairman of the working group on abdominal oncology of the German Cancer Society, drafting clinical guidelines for the treatment of colorectal and pancreatic cancer.

Chairman of the Oncology Society of North Rhine-Westphalia.

Member of the Colorectal Cancer Clinical Guidelines Working Group, European Society for Medical Oncology.

Member of the Scientific Council, National Cancer Registry at the Robert Koch Institute.

Chairman of the Regional Cancer Registry of the State of North Rhine-Westphalia.

Leading expert for clinical research, German Research Foundation and Federal Ministry of Research and Technology.

Member of the Commission on the Use of Medicines for Therapy "Off-Label", Federal Institute of Medicines and Medical Devices.

Member of the committee for the development of clinical guidelines for colorectal cancer.

Member of the commission on the development of approaches to metastasis and the use of palliative therapy in clinical guidelines for colorectal cancer.

Reviewer of scientific journals such as Journal of Cancer Research and Clinical Oncology, Tumor Diagnostik und Therapie, Der Schmerz, BMC Pharmacology, Onkologie, Strahlentherapie und Onkologie, International Journal of Colorectal Disease, Annuals of Oncology, European Journal of Cancer.